The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.
Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, Chang HY, Werb Z.
Littlepage LE, et al. Among authors: sternlicht md.
Cancer Discov. 2012 Jul;2(7):638-51. doi: 10.1158/2159-8290.CD-12-0093. Epub 2012 May 10.
Cancer Discov. 2012.
PMID: 22728437
Free PMC article.